Topic

Jane E. Remillard is the leader of the Life Sciences Intellectual Property Team at Nelson Mullins, jane.remillard@nelsonmullins.com.

Jill Gorny Sloper is a partner at Nelson Mullins with a focus on patent law in the biotechnology, pharmaceutical, and life science fields, jill.sloper@nelsonmullins.com.

Articles

Stringent patentability requirements present a challenge to obtaining broad-based antibody claims, so companies should develop a strategy based on multiple reinforcing layers of protection. 

Patentability Considerations for Antibody-Related Inventions

Catalent has unveiled investment plans to create a European center of excellence for clinical biologics formulation development and drug product fill/finish services.

Catalent Invests Millions to Create European Clinical Manufacturing Center of Excellence

A strong immune response by patients receiving two doses of AZD1222 vaccine suggests a possible dosing strategy for COVID-19 vaccine.

AstraZeneca/Oxford Vaccine Shows Antibody and T-cell Responses

VAR2 Pharmaceuticals has been selected for its development of a drug-conjugated malaria protein that potentially selectively binds to most human tumor types.


VAR2 Pharmaceuticals Wins MilliporeSigma’s Advance Biotech Grant

The company now offers its CONFIDENCE virus clearance services to support validation of viral clearance processes.

Sartorius Stedim Biotech Launches Consultancy Services for Viral Clearance Validation

Citing clinical trial data that hydroxychloroquine did not show benefits for COVID-19 patients, FDA removes emergency use authorization for the drug as a treatment for the novel coronavirus. 

FDA Revokes EUA for Hydroxychloroquine

Novavax announces DoD contract to produce 10 million doses of COVID-19 vaccine candidate. 

Novavax Secures $60 Million in Government Funds

The companies have entered into a manufacturing agreement for the fill finish supply of lenzilumab for the potential treatment of COVID-19.

Ajinomoto Bio-Pharma Services, Humanigen in Manufacturing Agreement for COVID-19 Biologic

The acquisition gives Novovax an annual operating capacity of more that one billion doses of COVID-19 vaccine antigen.

Novavax Acquires Praha Vaccines, Expands Large-Scale Vaccine Manufacturing Capacity

Achieving herd immunity will require testing, data, a vaccine, and public support.

BioBusiness